Featured News

The Celiac Disease Foundation is proud to have been involved by recruiting patients essential for this trial’s success.

The ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.

We are pleased to share that CEO Marilyn Geller will be presenting as the Patient Advocate at the March 18-19 National Institute of Allergy and Infectious Diseases Accelerating Progress in Celiac Disease Workshop. We encourage you to register to attend this seminal virtual meeting.

The Senate Appropriations Committee has released their FY2021 funding recommendations, which includes report language directing NIH to support celiac disease research.

The Society for the Study of Celiac Disease (SSCD) has released a statement on the COVID-19 vaccination and its safety for celiac disease patients.

A new study suggests a high dose of gluten might protect infants from celiac disease. However, other experts warn that the evidence shows a benefit only for introducing normal amounts of wheat to breastfed babies 4-6 months old.

The ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.

Celiac Disease Foundation Young Investigator Award recipient Jocelyn Silvester, MD, publishes “A new diagnostic paradigm for celiac disease.”

Researchers from Takeda Pharmaceuticals and the Celiac Disease Foundation presented a study which concluded that despite gluten-free diet adherence, many patients with celiac disease still have symptoms that substantially impact their lives.

A study led by Columbia University and Celiac Disease Foundation researchers examined probiotic use among celiac disease patients and was an Outstanding Poster Presenter recipient at the 2020 ACG Annual Scientific Meeting.